Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells

摘要

BackgroundAberrant expression and activation of the IGF-IR have been reported in a variety of human cancers and have been associated with resistance to HER targeted therapy. In this study, we investigated the effect of simultaneous targeting of IGF-IR and HER (erbB) family, with NVP-AEW541 and afatinib, on proliferation of pancreatic cancer cells.